BioSpace News Archive

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs

First dose of potential treatment AT-1501 given to humans by Anelixis Therapeutics to determine safety and tolerability

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Dr Joseph D Khoury as a Scientific Advisor to the Company’s established Scientific Advisory Board.

The second edition of ‘Aqdar World Summit’, launched in Abu Dhabi on November 26, concluded on Wednesday at the Abu Dhabi National Exhibition Centre -ADNEC.

“I wanted to create a quick and easy way to treat skin ulcers,” said an inventor, from Fancy Gap, Va., “so I invented the ULTIMATE ULCER CREAM.”

Food and Drug Administration (FDA) today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Brammer Bio (“Brammer”), a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO), was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program.

Scientists have uncovered that an emerging gene therapy for Parkinson’s disease creates new circuits in the brain associated with improved motor movement.

In the ultimate act of service during Chicago’s cold holiday season, Midwest Orthopaedic at Rush (MOR) physicians and their staff, and medical students from Rush University Medical Center will provide complimentary foot health care and distribute socks and winter boots to homeless men and women at a shelter on Chicago’s west side.